Crescent Biopharma
CBIO
81 hedge funds and large institutions have $428M invested in Crescent Biopharma in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 12 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.03% less ownership
Funds ownership: 1.08% → 1.05% (-0.03%)
5% less funds holding
Funds holding: 85 → 81 (-4)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
36% less capital invested
Capital invested by funds: $668M → $428M (-$240M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$3.87M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.75M |
| 3 |
Axa
Paris,
France
|
+$2.21M |
| 4 |
Man Group
London,
United Kingdom
|
+$2.21M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$6.48M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.12M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$5.76M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.26M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.65M |
CBIO Hedge Fund Activity: Q4 2018 in Review
81 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2018, worth a combined $428M — down 36% from $668M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CBIO and 9 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 28 added.
The largest buyer was OppenheimerFunds, adding an estimated $3.87M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $6.48M sold.
- 81 institutional investors held Crescent Biopharma (CBIO) as of Q4 2018, down from 85 in Q3 2018.
- Funds reported $428M of Crescent Biopharma stock for Q4 2018, down 36% quarter-over-quarter.
- 9 funds opened new Crescent Biopharma positions in Q4 2018 and 12 closed out, a net change of -3 holders.
- The largest Crescent Biopharma buyer in Q4 2018 was OppenheimerFunds, an estimated $3.87M added.
- The largest Crescent Biopharma seller in Q4 2018 was Alyeska Investment Group, an estimated $6.48M sold.
Based on aggregated 13F filings for Q4 2018.